

Table 4: Endpoint: Pain level  $\geq 2$ . Association of demographic and clinical characteristics with incident neuropathic pain. Univariable analysis using logistic mixed-effects regression. N=567 subjects, 2734 visits.

	Group	OR	95% CI	LRT P-value
Age	per yr	1.058	(1.019, 1.098)	0.0025
Gender	Women	Ref		0.18
	Men	0.60	(0.29, 1.27)	
Ethnicity	White	Ref		0.095
	Black	0.46	(0.24, 0.89)	
	Hispanic	0.46	(0.15, 1.44)	
	Other	0.33	(0.04, 2.88)	
CART Use at Study Entry	Never	Ref		0.16
	Current	2.21	(0.941, 5.17)	
	Past	2.31	(0.73, 7.32)	
Current CART Use	Never	Ref		0.22
	Current	2.30	(0.86, 6.11)	
	Past	2.03	(0.67, 6.15)	
D-drug Use	Never	Ref		0.064
	Current	0.77	(0.24, 2.45)	
	Past	1.84	(0.986, 3.45)	
Current CD4 < 200	$\geq 200$	Ref		0.85
	< 200	0.937	(0.47, 1.87)	
Nadir CD4 < 200	$\geq 200$	Ref		0.32
	< 200	1.34	(0.75, 2.38)	
Plasma HIV VL at Study Entry	Undetectable	Ref		0.88
	Detectable	0.951	(0.51, 1.79)	
Time-updated Detectable Plasma HIV VL	Undetectable	Ref		0.89
	Detectable	0.971	(0.64, 1.47)	
HIV Duration	per month	1.0034	(0.99928, 1.0075)	0.10
Hepatitis C Serostatus	Negative	Ref		0.14
	Positive	1.62	(0.86, 3.08)	
Diabetes Mellitus	No DM2	Ref		0.55
	DM2	0.70	(0.21, 2.33)	
Triglycerides	per unit	1.00033	(0.9964, 1.0043)	0.87
Time-updated Depressive Symptoms (BDI-II)	0-13	Ref		0.0034
	14-19	1.17	(0.66, 2.08)	
	20-28	2.14	(1.20, 3.82)	
	29-63	3.55	(1.71, 7.41)	
Lifetime History of Any Substance Abuse/Dependence	No	Ref		0.50
	Yes	1.27	(0.63, 2.53)	
Alcohol: History of Ab/Dep	No	Ref		0.37
	Yes	1.33	(0.71, 2.47)	
Methamphetamine: History of Ab/Dep	No	Ref		0.98
	Yes	1.011	(0.45, 2.29)	
Cocaine: History of Ab/Dep	No	Ref		0.35
	Yes	1.35	(0.72, 2.52)	
Opioids: History of Ab/Dep	No	Ref		0.040
	Yes	2.31	(1.047, 5.08)	

Table 5: Endpoint: Pain level  $\geq 2$ . Association of demographic and clinical characteristics with incident neuropathic pain. Univariable analysis using logistic mixed-effects regression: variables showing interaction with follow-up time.

	Group	Effect at 1 year: OR (95% CI)	Yearly Change: OR (95% CI)	Interacti
CD4 < 200 at Study Entry	$\geq 200$	Ref	1.25 (1.105, 1.40)	0.014
	< 200	1.43 (0.57, 3.61)	0.88 (0.68, 1.14)	
Height	66in (25th %-ile)	1.34 (1.037, 1.72)	1.062 (0.934, 1.21)	0.0042
	69in (50th %-ile)	Ref	1.21 (1.086, 1.36)	
	71in (75th %-ile)	0.82 (0.70, 0.976)	1.33 (1.15, 1.52)	
Depressive Symptoms at Study Entry (BDI-II)	0-13	Ref	1.36 (1.17, 1.57)	0.0050
	14-19	2.65 (1.015, 6.93)	1.16 (0.89, 1.53)	
	20-28	2.62 (1.033, 6.63)	0.930 (0.71, 1.22)	
	29-63	3.45 ( 1.16, 10.29)	0.79 (0.56, 1.097)	

Table 6: Subjects without DSPN at baseline. Endpoint: Pain level  $\geq 2$ . Multivariable logistic mixed-effects regression model for incident neuropathic pain  $\geq 2$  and symptoms. N=567 subjects, 2734 visits.

	Group	OR (95% CI)	P-value
Follow-up Time	per yr	1.13 (1.0064, 1.27)	0.034
Age	per yr	1.054 (1.015, 1.095)	0.0054
Time-updated Depr. Sympt. (BDI-II)	0-13	Ref	0.0013
	14-19	1.20 (0.67, 2.15)	
	20-28	2.16 (1.20, 3.89)	
	29-63	3.43 (1.64, 7.15)	
Opioid use	Yes vs No	2.35 (1.055, 5.21)	0.039

Table 7: Subjects without DSPN at baseline. Endpoint: Signs + Symptoms, Pain level  $\geq 1$ . Association of demographic and clinical characteristics with incident DSPN. Univariable analysis using logistic mixed-effects regression. N=532 subjects, 2572 visits.

	Group	OR	95% CI	LRT P-value
Age	per yr	1.069	(1.028, 1.11)	0.00064
Gender	Women	Ref		0.048
	Men	0.47	(0.22, 0.9933)	
Ethnicity	White	Ref		0.95
	Black	0.86	(0.43, 1.70)	
	Hispanic	1.042	(0.35, 3.07)	
	Other	1.25	(0.20, 7.98)	
CART Use at Study Entry	Never	Ref		0.0041
	Current	3.73	(1.49, 9.33)	
	Past	5.91	(1.79, 19.57)	
D-drug Use	Never	Ref		0.0026
	Current	2.04	(0.69, 6.07)	
	Past	3.09	(1.61, 5.95)	
Current CD4 < 200	$\geq 200$	Ref		0.20
	< 200	1.52	(0.81, 2.87)	
Nadir CD4 < 200	$\geq 200$	Ref		0.021
	< 200	2.08	(1.105, 3.91)	
Plasma HIV VL at Study Entry	Undetectable	Ref		0.84
	Detectable	0.935	(0.49, 1.78)	
Time-updated Detectable Plasma HIV VL	Undetectable	Ref		0.81
	Detectable	1.053	(0.70, 1.59)	
HIV Duration	per month	1.0048	(1.00049, 1.0091)	0.027
Hepatitis C Serostatus	Negative	Ref		0.041
	Positive	1.99	(1.029, 3.83)	
Diabetes Mellitus	No DM2	Ref		0.53
	DM2	1.43	(0.48, 4.27)	
Triglycerides	per unit	0.9985	(0.9945, 1.0026)	0.48
Depressive Symptoms at Study Entry (BDI-II)	0-13	Ref		0.087
	14-19	2.00	(0.77, 5.17)	
	20-28	2.69	(1.15, 6.31)	
	29-63	0.90	(0.27, 2.94)	
	Time-updated Depressive Symptoms (BDI-II)	0-13	Ref	
	14-19	1.92	(1.11, 3.34)	
	20-28	2.17	(1.15, 4.07)	
	29-63	2.81	(1.25, 6.31)	
Lifetime History of Any Substance Abuse/Dependence	No	Ref		0.30
	Yes	1.46	(0.72, 2.96)	
Alcohol: History of Ab/Dep	No	Ref		0.41
	Yes	1.31	(0.69, 2.47)	
Methamphetamine: History of Ab/Dep	No	Ref		0.70
	Yes	0.85	(0.37, 1.96)	
Cocaine: History of Ab/Dep	No	Ref		0.091
	Yes	1.74	(0.915, 3.30)	
Opioids: History of Ab/Dep	No	Ref		0.014
	Yes	2.75	(1.24, 6.14)	

Table 8: Endpoint: Signs + Pain level  $\geq 1$ . Association of demographic and clinical characteristics with incident neuropathic pain. Univariable analysis using logistic mixed-effects regression: variables showing interaction with follow-up time.

	Group	Effect at 1 year: OR (95% CI)	Yearly Change: OR (95% CI)	Interaction P-value
Current CART Use	Never	Ref	2.73 (1.32, 5.64)	0.018
	Current	16.96 (2.92, 98.37)	1.060 (0.944, 1.19)	
	Past	23.58 (3.72, 149.52)	0.88 (0.60, 1.30)	
CD4 < 200 at Study Entry	$\geq 200$	Ref	1.17 (1.029, 1.32)	0.038
	< 200	2.96 (1.26, 7.00)	0.90 (0.72, 1.11)	
Height	66in (25th %-ile)	1.33 (1.036, 1.71)	0.9975 (0.87, 1.14)	0.033
	69in (50th %-ile)	Ref	1.098 (0.982, 1.23)	
	71in (75th %-ile)	0.83 (0.70, 0.977)	1.17 (1.028, 1.33)	

Table 9: Subjects without DSPN at baseline. Endpoint: signs + symptoms, pain level  $\geq 1$ . Multivariable logistic mixed-effects regression model for incident neuropathic pain  $\geq 1$  and symptoms. N=532 subjects, 2572 visits.

	Group	OR (95% CI)	P-value
Follow-up Time	per yr	0.9921 (0.88, 1.12)	1.00
Age	per yr	1.067 (1.027, 1.11)	0.0018
Gender	Male vs Female	0.46 (0.22, 0.933)	0.072
CART (Time-updated)	Never	Ref	0.0041
	Current	5.22 ( 1.51, 18.07)	
	Past	6.47 ( 1.70, 24.67)	
CD4 < 200 at Study Entry	$\leq 200$ vs $>200$	1.80 (0.82, 3.93)	0.16
Time-updated Depr. Sympt. (BDI-II)	0-13	Ref	0.0017
	14-19	2.10 (1.21, 3.65)	
	20-28	2.32 (1.24, 4.36)	
	29-63	2.47 (1.11, 5.52)	
Opioid use	Yes vs No	2.03 (0.938, 4.39)	0.054

Table 10: Subjects without DSPN at baseline. Endpoint: signs + symptoms, pain level  $\geq 2$ . Association of demographic and clinical characteristics with incident neuropathic pain  $\geq 2$  and symptoms. Univariable analysis using logistic mixed-effects regression. N=579 subjects, 2866 visits.

	Group	OR	95% CI	LRT P-value
Age	per yr	1.093	(1.044, 1.14)	<0.0001
Ethnicity	White	Ref		0.41
	Black	0.53	(0.25, 1.13)	
	Hispanic	0.57	(0.16, 2.06)	
	Other	0.65	(0.06, 6.44)	
CART Use at Study Entry	Never	Ref		0.11
	Current	2.47	(0.919, 6.65)	
	Past	1.18	(0.29, 4.82)	
Current CART Use	Never	Ref		0.067
	Current	4.06	( 1.12, 14.70)	
	Past	3.57	( 0.84, 15.17)	
D-drug Use	Never	Ref		0.037
	Current	1.33	(0.38, 4.68)	
	Past	2.48	(1.19, 5.18)	
Current CD4 < 200	$\geq 200$	Ref		0.52
Nadir CD4 < 200	< 200	1.27	(0.61, 2.65)	
	$\geq 200$	Ref		0.076
Plasma HIV VL at Study Entry	< 200	1.85	(0.929, 3.69)	
	Undetectable	Ref		0.53
Time-updated Detectable Plasma HIV VL	Detectable	0.80	(0.39, 1.62)	
	Undetectable	Ref		0.17
HIV Duration	per month	1.0050	(1.00021, 1.0098)	0.038
Hepatitis C Serostatus	Negative	Ref		0.095
	Positive	1.85	(0.90, 3.80)	
Diabetes Mellitus	No DM2	Ref		0.88
	DM2	0.90	(0.23, 3.45)	
Triglycerides	per unit	1.0021	(0.9975, 1.0067)	0.37
Time-updated Depressive Symptoms (BDI-II)	0-13	Ref		0.072
	14-19	1.11	(0.60, 2.06)	
	20-28	1.75	(0.89, 3.42)	
	29-63	3.02	(1.26, 7.27)	
Lifetime History of Any Substance Abuse/Dependence	No	Ref		0.76
	Yes	1.13	(0.52, 2.47)	
Alcohol: History of Ab/Dep	No	Ref		0.97
	Yes	1.015	(0.50, 2.06)	
Methamphetamine: History of Ab/Dep	No	Ref		0.68
	Yes	0.82	(0.31, 2.15)	
Cocaine: History of Ab/Dep	No	Ref		0.32
	Yes	1.44	(0.70, 2.96)	
Opioids: History of Ab/Dep	No	Ref		0.041
	Yes	2.59	(1.054, 6.35)	
Height	per inch	0.958	(0.88, 1.048)	0.34

Table 11: Endpoint: Signs + Pain level  $\geq 2$ . Association of demographic and clinical characteristics with incident neuropathic pain. Univariable analysis using logistic mixed-effects regression: variables showing interaction with follow-up time.

	Group	Effect at 1 year: OR (95% CI)	Yearly Change: OR (95% CI)	Interaction P-value
Gender	Female	Ref	0.977 (0.73, 1.31)	0.043
	Male	0.53 (0.21, 1.31)	1.36 (1.19, 1.54)	
CD4 < 200 at Study Entry	$\geq 200$	Ref	1.42 (1.24, 1.63)	0.0031
	< 200	2.13 (0.75, 6.05)	0.932 (0.73, 1.19)	
Depressive Symptoms at Study Entry (BDI-II)	0-13	Ref	1.37 (1.18, 1.60)	0.035
	14-19	1.90 (0.62, 5.76)	1.38 (1.016, 1.88)	
	20-28	1.79 (0.61, 5.22)	1.26 (0.923, 1.72)	
	29-63	2.88 (0.82, 10.13)	0.73 (0.48, 1.12)	

Table 12: Subjects without DSPN at baseline. Endpoint: signs + symptoms, pain level  $\geq 2$ . Multivariable logistic mixed-effects regression model for incident neuropathic pain  $\geq 2$  and symptoms. N=579 subjects, 2866 visits.

	Group	OR (95% CI)	P-value
Follow-up Time	per yr	1.14 (1.0061, 1.30)	0.040
Age	per yr	1.091 (1.042, 1.14)	1e-04
Current CART Use	Never	Ref	0.066
	Current	4.49 (1.12, 18.02)	
	Past	3.95 (0.84, 18.51)	
Opioid use	Yes vs No	1.091 (1.042, 1.14)	0.050